Kineta Revenue 2014-2024 | KANT
Kineta revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Kineta Annual Revenue
(Millions of US $) |
| 2023 |
$5 |
| 2022 |
$2 |
| 2021 |
$9 |
| 2020 |
$7 |
| 2019 |
$ |
| 2018 |
$3 |
| 2017 |
$5 |
| 2016 |
$8 |
| 2015 |
$4 |
| 2014 |
$5 |
| 2013 |
$1 |
Kineta Quarterly Revenue
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$0 |
| 2023-09-30 |
|
| 2023-06-30 |
$5 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$2 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$4 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$5 |
| 2018-12-31 |
|
| 2018-09-30 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$2 |
| 2017-09-30 |
$2 |
| 2017-06-30 |
$1 |
| 2017-03-31 |
$1 |
| 2016-12-31 |
$4 |
| 2016-09-30 |
$2 |
| 2016-06-30 |
$1 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$1 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
